Why Aura Biosciences, Inc.’s (AURA) Stock Is Down 8.21%
As of Wednesday, August 12, Aura Biosciences, Inc.’s AURA share price has dipped by 8.21%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company’s proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Aura Biosciences, Inc.’s (AURA) Stock Is Up 8.69%
As of Thursday, July 02, Aura Biosciences, Inc.’s AURA share price has surged by 8.69%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Aura Biosciences, Inc.’s (AURA) Stock Is Down 7.19%
As of Wednesday, May 06, Aura Biosciences, Inc.’s AURA share price has dipped by 7.19%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Aura Biosciences, Inc.’s (AURA) Stock Is Up 5.51%
As of Tuesday, May 05, Aura Biosciences, Inc.’s AURA share price has surged by 5.51%, which has investors questioning if this is right time to sell.Michael Rose
Why Aura Biosciences, Inc.’s (AURA) Stock Is Up 12.40%
As of Tuesday, May 05, Aura Biosciences, Inc.’s AURA share price has surged by 12.40%, which has investors questioning if this is right time to sell.Tudor Pop
Financial Summary
| Share Statistics | AURA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $784.0 | $280.5 | 42% |
|
| Shares Out (Mil) | 94.9 | 53.9 | 61% |
|
| Institutional Ownership | 98.0% | 92.9% | 77% |
|
| Float (Mil) | 79.6 | 41.9 | 57% |
|
| Beta | 0.40 | 0.94 | 23% |
|
| Avg Daily Volume (000s) | 638 | 480 | 64% |
|
| Price Change (52-week) |
17.8% | 59.8% | 62% |
|
| Growth | AURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (36.8%) | (10.1%) | 11% |
|
| EPS (5yr) | 53.6% | 15.8% | 94 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 15.0% | (15.6%) | 73% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | AURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($131) | ($43) | 9% |
|
| EPS (TTM) | ($1.773) | ($1.500) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($103) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($40) | $2 | 21% |
|
| Long-Term Debt (Q1) (Mil) | $13 | $4 | 30% |
|
| Enterprise Value (Q1) (Mil) | $502 | $182 | 34% |
|
| Valuation | AURA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.48 | 2.81 | 58% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | AURA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (47.4%) | (47.8%) | 12% |
|
| ROE | (53.5%) | (55.0%) | 15% |
|
| Liabilities to Assets | 9.4% | 30.0% | 6% |
|
| F-Score | 4 | 3 | 33% |
|
Aura Biosciences, Inc. did not pass any screens on 9/4/2026.
